Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs
US agency’s advisory committees will consider whether ongoing trial of exon 45- and 53-skipping compounds for Duchenne muscular dystrophy should allow use of in-dwelling ports to aid infusion.
